Characteristics of residual invasive breast cancer after neoadjuvant therapy in the KATHERINE study

被引：2
|
作者：
Mamounas, E. P. [1 ]
机构：
[1] Orlando Hlth Canc Inst, NSABP Fdn & Dept Surg, Orlando, FL USA
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷 / 09期
关键词：
TRASTUZUMAB; DISEASE; T-DM1;
D O I：
10.1016/j.annonc.2021.05.802
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1191 / 1192
页数：2
相关论文
共 50 条
  • [1] Biomarkers of residual disease after neoadjuvant therapy for breast cancer
    Penault-Llorca, Frederique
    Radosevic-Robin, Nina
    NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (08) : 487 - 503
  • [2] Biomarkers of residual disease after neoadjuvant therapy for breast cancer
    Frederique Penault-Llorca
    Nina Radosevic-Robin
    Nature Reviews Clinical Oncology, 2016, 13 : 487 - 503
  • [3] Prognostication of genomic characteristics of residual breast cancer after neoadjuvant chemotherapy
    Kim, Ji-Yeon
    Park, Sabin
    Ahn, Sepil
    Seo, Eun Seop
    Kim, Soyeon
    Gregory, Mark
    Killingbeck, Emily
    Cho, Eun Yoon
    Lee, Jeong Eon
    Ahn, Jin Seok
    Park, Yeon Hee
    Park, Woong-Yang
    Kim, Hoon
    Lee, Semin
    Im, Young-Hyuck
    CANCER RESEARCH, 2024, 84 (06)
  • [4] Prognostic Significance of Residual Ductal Carcinoma In Situ After Complete Response of Invasive Breast Cancer to Neoadjuvant Therapy
    O'Keefe, Thomas J.
    Wallace, Anne M.
    JAMA SURGERY, 2023, 158 (06) : 674 - 675
  • [5] Residual Disease after Neoadjuvant Therapy for Breast Cancer: Can MRI Help?
    Hylton, Nola M.
    RADIOLOGY, 2018, 289 (02) : 335 - 336
  • [6] Heterogeneity of Residual Disease After Neoadjuvant Systemic Therapy in Breast Cancer A Review
    Tarantino, Paolo
    Hortobagyi, Gabriel
    Tolaney, Sara M.
    Mittendorf, Elizabeth A.
    JAMA ONCOLOGY, 2024,
  • [7] Prognostic Significance of Residual Ductal Carcinoma In Situ After Complete Response of Invasive Breast Cancer to Neoadjuvant Therapy Reply
    Mukhtar, Rita A.
    Yau, Christina
    Esserman, Laura J.
    JAMA SURGERY, 2023, 158 (06) : 675 - 675
  • [8] Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer
    Denkert, Carsten
    Lambertini, Chiara
    Fasching, Peter A.
    Pogue-Geile, Katherine L.
    Mano, Max S.
    Untch, Michael
    Wolmark, Norman
    Huang, Chiun-Sheng
    Loibl, Sibylle
    Mamounas, Eleftherios P.
    Geyer Jr, Charles E.
    Lucas, Peter C.
    Boulet, Thomas
    Song, Chunyan
    Lewis, Gail D.
    Nowicka, Malgorzata
    de Haas, Sanne
    Basik, Mark
    CLINICAL CANCER RESEARCH, 2023, 29 (08) : 1569 - 1581
  • [9] Efficacy of breast conserving treatment of minimal residual tumors after neoadjuvant therapy for breast cancer
    Pesotsky, Roman
    Semiglazov, Vladimir
    Krivorotko, Petr
    Tabagua, Tengiz
    Zernov, Konstantin
    Emelyanov, Alexander
    Mortada, Viktoria
    Amirov, Nikolay
    Ulrikh, Daria
    Levchenko, Valerii
    Bondarchuk, Yana
    Enaldieva, Diana
    Bekkeldieva, Nestan
    Zirov, Konsantin
    Yerechshenko, Sergey
    Evseev, Vladislav
    Rychagov, Kirill
    Novikov, Sergey
    Kazantseva, Maria
    Gigolaeva, Larisa
    Zhiltsova, Elena
    Nesterov, Denis
    Ivanova, Olga
    Semiglazova, Tatiana
    CANCER RESEARCH, 2024, 84 (09)
  • [10] Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE
    Mamounas, E. P.
    Untch, M.
    Mano, M. S.
    Huang, C-S
    Geyer, C. E., Jr.
    von Minckwitz, G.
    Wolmark, N.
    Pivot, X.
    Kuemmel, S.
    DiGiovanna, M. P.
    Kaufman, B.
    Kunz, G.
    Conlin, A. K.
    Alcedo, J. C.
    Kuehn, T.
    Wapnir, I
    Fontana, A.
    Hackmann, J.
    Polikoff, J.
    Saghatchian, M.
    Brufsky, A.
    Yang, Y.
    Zimovjanova, M.
    Boulet, T.
    Liu, H.
    Tesarowski, D.
    Lam, L. H.
    Song, C.
    Smitt, M.
    Loibl, S.
    ANNALS OF ONCOLOGY, 2021, 32 (08) : 1005 - 1014
12345